Overview
Anemia is a common complication in patients with end-stage renal disease (ESRD), significantly impacting their quality of life and prognosis. It is often multifactorial, with erythropoietin deficiency being a primary contributor.Diagnosis
Diagnosis of anemia in ESRD is typically based on hemoglobin levels below established thresholds, considering the patient's clinical context 1.Management
The management of anemia in ESRD primarily involves erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels.
For patients with atrial fibrillation and ESRD requiring anticoagulation, direct oral anticoagulants (DOACs) are associated with a lower risk of major bleeding compared to vitamin K antagonists (VKAs) 1.
DOACs and VKAs demonstrated equivalent efficacy in preventing thromboembolism, although dabigatran and rivaroxaban were associated with fewer embolic events 1.
No significant differences in all-cause mortality were observed between DOACs, VKAs, and no anticoagulation in this population 1.Special Populations
For dialysis-dependent patients with atrial fibrillation, DOACs are recommended over VKAs due to a lower risk of major bleeding 1.Key Recommendations
For dialysis-dependent patients with atrial fibrillation, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs) due to a lower risk of major bleeding 1. (Evidence: Strong)
DOACs and VKAs are equally effective in preventing thromboembolism in dialysis-dependent patients with atrial fibrillation 1. (Evidence: Strong)
There is no difference in all-cause mortality when comparing DOACs, VKAs, or no anticoagulation in dialysis-dependent patients with atrial fibrillation 1. (Evidence: Strong)References
1 Kao TW, Chen ZW, Lin YH. Anticoagulation for Patients With Concomitant Atrial Fibrillation and End-Stage Renal Disease: A Systematic Review and Network Meta-Analysis. Journal of the American Heart Association 2024. link